OCUL EBITDA | OCULAR THERAPEUTIX, INC

OCULAR THERAPEUTIX, INC (OCUL) EBITDA

2026-06-30: Basis Reported; EBITDA -$80.26M*; Operating income -$82.11M; Depreciation and amortization $1.85M*.
2026-03-31: Basis Reported; EBITDA -$92.06M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$68.51M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$67.63M*; Operating income -$68.70M; Depreciation and amortization $1.07M*.

Complete source-backed ebitda history.

Available history: 2012-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$80.26M*	-$82.11M	$1.85M*	$13.47M	-595.61%*	$3.37M*	-$67.27M*	$2.01M	$54.14M	(m)	(m)
2026-03-31	Reported	-$92.06M	(m)	(m)	(m)	-853.57%	$4.66M	-$65.99M	$1.33M	$66.21M	(m)	(m)
2025-12-31	Reported	-$68.51M	(m)	(m)	(m)	-517.08%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$67.63M*	-$68.70M	$1.07M*	$14.54M	-465.00%*	$5.99M*	-$50.73M*	$1.77M	$52.36M	(m)	(m)
2025-06-30	Reported	-$66.61M*	-$67.64M	$1.03M*	$13.46M	-494.95%*	$1.25M*	-$55.24M*	$1.94M	$51.08M	(m)	(m)
2025-03-31	Reported	-$62.94M	(m)	(m)	(m)	-588.30%	$1.93M	-$44.67M	$1.26M	$42.86M	(m)	(m)
2024-12-31	Reported	-$49.63M	(m)	(m)	(m)	-290.51%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$45.04M*	-$46.00M	$959.00K*	$15.43M	-291.99%*	$89.00K*	-$36.56M*	$1.56M	$37.05M	(m)	(m)
2024-06-30	Reported	-$42.63M*	-$43.59M	$956.00K*	$16.44M	-259.32%*	$742.00K*	-$24.80M*	$1.51M	$28.86M	(m)	(m)
2024-03-31	Reported	-$30.7M	(m)	(m)	(m)	-207.78%	$255.00K	-$33.89M	$1.33M	$20.73M	(m)	(m)
2023-12-31	Reported	-$19.09M	(m)	(m)	(m)	-128.99%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$18.32M*	-$19.21M	$890.00K*	$15.08M	-121.50%*	$259.00K*	-$7.73M*	$1.38M	$15.02M	(m)	(m)
2023-06-30	Reported	-$19.92M*	-$20.57M	$652.00K*	$15.19M	-131.16%*	$1.99M*	-$20.07M*	$1.30M	$15.09M	(m)	(m)
2023-03-31	Reported	-$22.07M	(m)	(m)	(m)	-164.99%	$3.38M	-$19.97M	$1.21M	$14.75M	(m)	(m)
2022-12-31	Reported	-$18.87M	(m)	(m)	(m)	-134.07%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$21.04M*	-$21.54M	$509.00K*	$11.96M	-175.80%*	$794.00K*	-$13.17M*	$1.07M	$13.72M	(m)	(m)
2022-06-30	Reported	-$19.36M*	-$19.92M	$552.00K*	$12.27M	-157.87%*	$495.00K*	-$10.88M*	$1.16M	$13.10M	(m)	(m)
2022-03-31	Reported	-$17.28M	(m)	(m)	(m)	-131.01%	$276.00K	-$18.60M	$1.30M	$13.10M	(m)	(m)
2021-12-31	Reported	-$17.48M	(m)	(m)	(m)	-142.01%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$18.93M*	-$19.53M	$594.00K*	$12.15M	-155.81%*	$276.00K*	-$12.98M*	$1.31M	$12.72M	(m)	(m)
2021-06-30	Reported	-$19.62M*	-$20.23M	$611.00K*	$11.72M	-167.43%*	$129.00K*	-$20.06M*	$1.10M	$13.86M	(m)	(m)
2021-03-31	Reported	-$19.58M	(m)	(m)	(m)	-266.71%	$158.00K	-$17.36M	$892.00K	$10.93M	(m)	(m)
2020-12-31	Reported	-$13.68M	(m)	(m)	(m)	-186.09%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$13.34M*	-$14.01M	$665.00K*	$5.88M	-227.04%*	$214.00K*	-$13.66M*	$450.00K	$6.95M	(m)	(m)
2020-06-30	Reported	-$17.18M*	-$17.88M	$707.00K*	$1.57M	-1094.77%*	$125.00K*	-$14.80M*	$134.00K	$8.02M	(m)	(m)
2020-03-31	Reported	-$15.88M	(m)	(m)	(m)	-608.66%	$249.00K	-$18.85M	$819.00K	$6.10M	(m)	(m)
2019-12-31	Reported	-$20.73M	(m)	(m)	(m)	-918.75%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$22.48M*	-$23.14M	$669.00K*	$829.00K	-2711.10%*	$419.00K*	-$19.54M*	$806.00K	$10.23M	(m)	(m)
2019-06-30	Reported	-$21.00M*	-$21.60M	$598.00K*	$650.00K	-3230.92%*	$493.00K*	-$19.18M*	$552.00K	$9.41M	(m)	(m)
2019-03-31	Reported	-$19.07M	(m)	(m)	(m)	-3875.81%	$725.00K	-$19.39M	$128.00K	$11.32M	(m)	(m)
2018-12-31	Reported	-$16.7M	(m)	(m)	(m)	-3313.69%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$14.24M*	-$14.82M	$573.00K*	$498.00K	-2860.04%*	$473.00K*	-$10.87M*	$115.00K	$9.69M	(m)	(m)
2018-06-30	Reported	-$13.00M*	-$13.56M	$566.00K*	$648.00K	-2005.86%*	$556.00K*	-$12.23M*	$153.00K	$8.74M	(m)	(m)
2018-03-31	Reported	-$12.89M	(m)	(m)	(m)	-3791.18%	$381.00K	-$12.47M	$80.00K	$8.23M	(m)	(m)
2017-12-31	Reported	-$12.19M	(m)	(m)	(m)	-2502.67%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$14.71M*	-$15.20M	$482.00K*	(m)	(m)	$2.04M*	-$14.38M*	(m)	$8.13M	(m)	(m)
2017-06-30	Reported	-$17.98M*	-$18.34M	$354.00K*	(m)	(m)	$4.00M*	-$11.13M*	(m)	$8.12M	(m)	(m)
2017-03-31	Reported	-$15.41M	(m)	(m)	(m)	-3244.42%	$1.65M	-$14.58M	(m)	$6.73M	(m)	(m)
2016-12-31	Reported	-$12.22M	(m)	(m)	(m)	-2391.19%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$9.02M*	-$9.24M	$216.00K*	(m)	(m)	$869.00K*	-$7.33M*	(m)	$5.69M	(m)	(m)
2016-06-30	Reported	-$10.90M*	-$11.11M	$207.00K*	(m)	(m)	$243.00K*	(m)	(m)	$6.98M	(m)	(m)
2016-06-30	Reported	(m)	-$11.11M	(m)	(m)	(m)	(m)	(m)	(m)	$6.98M	(m)	(m)
2016-03-31	Reported	-$10.3M	(m)	(m)	(m)	-2249.78%	$127.00K	(m)	(m)	$7.07M	(m)	(m)
2015-12-31	Reported	-$10.08M	(m)	(m)	(m)	-2310.78%	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	-$10.98M*	-$11.17M	$194.00K*	(m)	(m)	$76.00K*	(m)	(m)	$8.26M	(m)	(m)
2015-06-30	Reported	-$9.45M*	-$9.63M	$187.00K*	(m)	(m)	$875.00K*	(m)	(m)	$6.74M	(m)	(m)
2015-03-31	Reported	-$6.94M	(m)	(m)	(m)	-1629.11%	$354.00K	(m)	(m)	$4.72M	(m)	(m)
2014-12-31	Reported	-$7.38M	(m)	(m)	(m)	-1461.98%	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	-$6.64M*	-$6.78M	$139.00K*	(m)	(m)	$274.00K*	(m)	(m)	$4.48M	(m)	(m)
2014-06-30	Reported	-$5.79M*	-$5.95M	$151.00K*	(m)	(m)	$248.00K*	(m)	(m)	$4.29M	(m)	(m)
2014-03-31	Reported	-$6.73M	(m)	(m)	(m)	-24933.33%	$297.00K	(m)	(m)	$4.96M	(m)	(m)
2013-12-31	Reported	(m)	-$3.42M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	(m)	-$3.44M	(m)	(m)	(m)	$109.00K*	(m)	(m)	$2.78M	(m)	(m)
2013-06-30	Reported	(m)	-$2.99M	(m)	(m)	(m)	(m)	(m)	(m)	$2.40M	(m)	(m)
2013-03-31	Reported	(m)	-$3.06M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$265.69M	(m)	(m)	(m)	-511.43%	$12.01M	-$204.88M	$6.57M	$197.10M	(m)	$0.00
2024-12-31	Reported	-$168M	(m)	(m)	(m)	-263.63%	$1.29M	-$134.68M	$5.63M	$127.64M	(m)	$0.00
2023-12-31	Reported	-$79.4M	(m)	(m)	(m)	-135.86%	$6.09M	-$70.23M	$5.28M	$61.05M	(m)	$0.00
2022-12-31	Reported	-$76.55M	(m)	(m)	(m)	-148.65%	$3.71M	-$59.60M	$4.54M	$53.46M	(m)	$0.00
2021-12-31	Reported	-$75.62M	(m)	(m)	(m)	-173.74%	$1.19M	-$65.55M	$4.41M	$50.08M	(m)	$0.00
2020-12-31	Reported	-$60.07M	(m)	(m)	(m)	-345.19%	$841.00K	-$53.55M	$2.08M	$28.69M	(m)	$0.00
2020-09-30	Rolling	(m)	-$69.91M*	(m)	$12.31M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$79.04M*	(m)	$7.26M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$82.76M*	(m)	$6.34M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$83.27M	(m)	(m)	(m)	-1970.00%	$2.24M	-$77.58M	$2.33M	$41.09M	(m)	$0.00
2019-12-31	Rolling	(m)	-$85.80M*	(m)	$4.23M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$81.68M*	(m)	$2.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$73.36M*	(m)	$2.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$65.32M*	(m)	$2.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$56.83M	(m)	(m)	(m)	-2855.88%	$1.89M	-$49.23M	$465.00K	$36.91M	(m)	$0.00
2018-12-31	Rolling	(m)	-$59.12M*	(m)	$1.99M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$54.55M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$54.93M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$59.71M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$60.3M	(m)	(m)	(m)	-3135.62%	$8.25M	-$50.47M	$457.00K	$30.88M	(m)	$0.00
2017-12-31	Rolling	(m)	-$61.92M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$61.68M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$55.72M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$42.45M	(m)	(m)	(m)	-2249.34%	$1.92M	-$34.00M	(m)	$27.07M	(m)	$0.00
2016-03-31	Rolling	(m)	-$41.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$37.44M	(m)	(m)	(m)	-2139.60%	$1.78M	-$33.74M	(m)	$26.61M	(m)	$0.00
2015-12-31	Rolling	(m)	-$38.20M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Rolling	(m)	-$35.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-06-30	Rolling	(m)	-$31.07M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-03-31	Rolling	(m)	-$27.38M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	-$26.55M	(m)	(m)	(m)	-3438.73%	$1.26M	(m)	(m)	$18.88M	(m)	$0.00
2014-12-31	Rolling	(m)	-$27.09M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Rolling	(m)	-$22.97M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-06-30	Rolling	(m)	-$19.63M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-03-31	Rolling	(m)	-$16.67M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	-$12.5M	(m)	(m)	(m)	(m)	$387.00K	(m)	(m)	$10.52M	(m)	$0.00
2013-12-31	Rolling	(m)	-$12.90M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	-$13.27M	(m)	(m)	(m)	-132670.00%	$203.00K	(m)	(m)	$11.54M	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Prestige Consumer Healthcare Inc. (PBH)	United States	$2.163B	13.03
Bausch Health Companies Inc. (BHC)		$2.113B	-1.68
Aurinia Pharmaceuticals Inc. (AUPH)		$2.207B	7.18
Braveheart Bio, Inc. (BRVE)	United States	$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
Zai Lab Ltd (ZLAB)		$2.241B	-113.34
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05